Results 31 to 40 of about 1,156,033 (197)

Necessity and feasibility of developing diagnosis and treatment guidelines for  cirrhotic ascites and hepatorenal syndrome with Chinese intellectual property rights

open access: yesZhongguo linchuang yanjiu, 2023
At pressent, there are many controversies in China about the recommendations in Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome (hereinafter referred to as the “Guidelines”) revised in 2021 ...
LIU Jianjun   +6 more
doaj   +1 more source

CAQ Corner: Basic concepts of transplant immunology

open access: yes, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Population Based Trends in the Incidence of Hospital Admission for the Diagnosis of Hepatorenal Syndrome: 1998–2011

open access: yesInternational Journal of Nephrology, 2016
Background and Objectives. Hepatorenal syndrome carries a high risk of mortality. Understanding the incidence and mortality trends in hepatorenal syndrome will help inform future studies regarding the safety and efficacy of potential therapeutic ...
Manish Suneja   +4 more
doaj   +1 more source

HEPATORENAL SYNDROME WITH ACUTE RENAL FAILURE IN PATIENTS WITH CHRONIC LIVER DISEASE: MODERN ASPECTS OF CLINICAL PRESENTATION AND INTENSIVE CARE

open access: yesКреативная хирургия и онкология, 2018
Introduction. Acute renal failure is considered a functional, progressive, oliguric, but reversible kidney disease that occurs due to severe liver disease with hepatic insufficiency.
R. R. Nagimullin   +2 more
doaj   +1 more source

Norepinephrine is More Effective Than Midodrine/Octreotide in Patients With Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial

open access: yesFrontiers in Pharmacology, 2021
Background: Terlipressin is the first-line pharmacological treatment for hepatorenal syndrome. When terlipressin is unavailable, midodrine/octreotide or norepinephrine, with albumin, represent the alternative treatments. The comparative efficacy of these
Eman Ibrahim El-Desoki Mahmoud   +4 more
doaj   +1 more source

Fucoidan alleviates the hepatorenal syndrome through inhibition organic solute transporter α/β to reduce bile acids reabsorption

open access: yesCurrent Research in Pharmacology and Drug Discovery, 2023
The high levels of bile acids are a critical factor in hepatorenal syndrome. Organic solute transporter α/β (Ostα/β) participate in bile acids reabsorption in the kidney.
Xiaojuan Zhao   +6 more
doaj   +1 more source

Acute Kidney Injury in Liver Cirrhosis

open access: yesDiagnostics, 2023
Acute kidney injury (AKI) is common in cirrhotic patients affecting almost 20% of these patients. While multiple etiologies can lead to AKI, pre-renal azotemia seems to be the most common cause of AKI.
Rose Mary Attieh, Hani M. Wadei
doaj   +1 more source

Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study

open access: yesInternational Journal of Nephrology, 2015
Background/Aims. Acute kidney injury is a common problem for patients with cirrhosis and is associated with poor survival. We aimed to examine the association between type of acute kidney injury and 90-day mortality. Methods.
Andrew S. Allegretti   +9 more
doaj   +1 more source

Terlipressin in combination with albumin as a therapy for hepatorenal syndrome in patients aged 65 years or older

open access: yesAnnals of Hepatology, 2023
Introduction and Objectives: Clinical data for older patients with advanced liver disease are limited. This post hoc analysis evaluated the efficacy and safety of terlipressin in patients aged ≥65 years with hepatorenal syndrome using data from 3 Phase ...
Muhammad A. Mujtaba   +8 more
doaj   +1 more source

Hepatorenal syndrome [PDF]

open access: yesWorld Journal of Gastroenterology, 2007
Hepatorenal syndrome (HRS) is a "functional" and reversible form of renal failure that occurs in patients with advanced chronic liver disease. The distinctive hallmark feature of HRS is the intense renal vasoconstriction caused by interactions between systemic and portal hemodynamics.
Sharon, Turban   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy